{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:10:35Z","timestamp":1792185035379,"version":"4.4.0"},"reference-count":113,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec id=\"ab-irv230005-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The rise of fentanyl and other high-potency synthetic opioids across US and Canada has been associated with increasing hospitalizations and unprecedented overdose deaths. Hospitalization is a critical touchpoint to engage patients and offer life-saving opioid use disorder (OUD) care when admitted for OUD or other medical conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-irv230005-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Clinical best practices include managing acute withdrawal and pain, initiating medication for OUD, integrating harm reduction principles and practices, addressing in-hospital substance use, and supporting hospital-to-community care transitions. Fentanyl complicates hospital OUD care. Fentanyl\u2019s high potency intensifies pain, withdrawal, and cravings and increases the risk for overdose and other harms. Fentanyl\u2019s unique pharmacology has rendered traditional techniques for managing opioid withdrawal and initiating buprenorphine and methadone inadequate for some patients, necessitating novel strategies. Further, co-use of opioids with stimulants drugs is common, and the opioid supply is unpredictable and can be contaminated with benzodiazepines, xylazine, and other substances. To address these challenges, clinicians are increasingly relying on emerging practices, such as low-dose buprenorphine initiation with opioid continuation, rapid methadone titration, and the use of alternative opioid agonists. Hospitals must also reconsider conventional approaches to in-hospital substance use and expand clinicians\u2019 understanding and embrace of harm reduction, which is a philosophy and set of practical strategies that supports people who use drugs to be safer and healthier without judgment, coercion, or discrimination. Hospital-to-community care transitions should ensure uninterrupted access to OUD care after discharge, which requires special consideration and coordination. Finally, improving hospital-based addiction care requires dedicated infrastructure and expertise. Preparing hospitals across the US and Canada to deliver OUD best practices requires investments in clinical champions, staff education, leadership commitment, community partnerships, quality metrics, and financing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-irv230005-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this review indicate that fentanyl creates increased urgency and new challenges for hospital OUD care. Hospital clinicians and systems have a central role in addressing the current drug crisis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2023.7282","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T11:33:07Z","timestamp":1714390387000},"page":"691","source":"Crossref","is-referenced-by-count":79,"title":["Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl"],"prefix":"10.1001","volume":"184","author":[{"given":"Honora","family":"Englander","sequence":"first","affiliation":[{"name":"Section of Addiction Medicine in General Internal Medicine and the Division of Hospital Medicine, Department of Medicine, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish P.","family":"Thakrar","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Bagley","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Rolley","sequence":"additional","affiliation":[{"name":"Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hyshka","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"irv230005r2","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.v118.12","article-title":"Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021.","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"key":"irv230005r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019\u201d.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2","key":"irv230005r6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229174","article-title":"National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality.","volume":"15","author":"Singh","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"irv230005r7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMp2204687","article-title":"Hospital standards of care for people with substance use disorder.","volume":"387","author":"Englander","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"irv230005r8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.12788\/jhm.3311","article-title":"A call to action: hospitalists\u2019 role in addressing substance use disorder.","volume":"15","author":"Englander","year":"2020","journal-title":"J Hosp Med"},{"issue":"4","key":"irv230005r9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/ADM.0000000000000915","article-title":"Causes of death in the 12 months after hospital discharge among patients with opioid use disorder.","volume":"16","author":"King","year":"2022","journal-title":"J Addict Med"},{"key":"irv230005r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.039","article-title":"Touchpoints\u2014opportunities to predict and prevent opioid overdose: a cohort study.","volume":"204","author":"Larochelle","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"irv230005r11","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"irv230005r12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.12788\/jhm.2736","article-title":"Planning and designing the Improving Addiction Care Team (IMPACT) for hospitalized adults with substance use disorder.","volume":"12","author":"Englander","year":"2017","journal-title":"J Hosp Med"},{"issue":"1","key":"irv230005r13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/ADM.0000000000000819","article-title":"Trust in hospital physicians among patients with substance use disorder referred to an addiction consult service: a mixed-methods study.","volume":"16","author":"King","year":"2022","journal-title":"J Addict Med"},{"key":"irv230005r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100031","article-title":"Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service.","volume":"2","author":"Nordeck","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"11","key":"irv230005r15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.12788\/jhm.2993","article-title":"\u201cWe\u2019ve learned it\u2019s a medical illness, not a moral choice\u201d: qualitative study of the effects of a multicomponent addiction intervention on hospital providers\u2019 attitudes and experiences.","volume":"13","author":"Englander","year":"2018","journal-title":"J Hosp Med"},{"key":"irv230005r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108708","article-title":"Experiences of stigma in hospitals with addiction consultation services: a qualitative analysis of patients\u2019 and hospital-based providers\u2019 perspectives.","volume":"138","author":"Hoover","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"irv230005r17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s11606-021-07362-8","article-title":"Inpatient addiction medicine consultation service impact on post-discharge patient mortality: a propensity-matched analysis.","volume":"37","author":"Wilson","year":"2022","journal-title":"J Gen Intern Med"},{"key":"irv230005r18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.socscimed.2014.01.010","article-title":"Hospitals as a \u2018risk environment\u2019: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs.","volume":"105","author":"McNeil","year":"2014","journal-title":"Soc Sci Med"},{"key":"irv230005r19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings.","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"irv230005r20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/08897077.2019.1671942","article-title":"Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study.","volume":"41","author":"Simon","year":"2020","journal-title":"Subst Abus"},{"issue":"4","key":"irv230005r21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/ADM.0000000000000314","article-title":"Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice.","volume":"11","author":"Wakeman","year":"2017","journal-title":"J Addict Med"},{"issue":"3","key":"irv230005r22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11606-016-3919-4","article-title":"\u201cIt\u2019s been an experience, a life learning experience\u201d: a qualitative study of hospitalized patients with substance use disorders.","volume":"32","author":"Velez","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"5","key":"irv230005r23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11606-002-0034-5","article-title":"Mutual mistrust in the medical care of drug users: the keys to the \u201cnarc\u201d cabinet.","volume":"17","author":"Merrill","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"1","key":"irv230005r24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12954-023-00893-9","article-title":"\u201cAs safe as possible\u201d: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids.","volume":"20","author":"Frank","year":"2023","journal-title":"Harm Reduct J"},{"issue":"4","key":"irv230005r25","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated qwithdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"4","key":"irv230005r26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"8","key":"irv230005r27","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","article-title":"Xylazine and overdoses: trends, concerns, and recommendations.","volume":"112","author":"Alexander","year":"2022","journal-title":"Am J Public Health"},{"issue":"1","key":"irv230005r28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13722-021-00221-1","article-title":"Adapting inpatient addiction medicine consult services during the COVID-19 pandemic.","volume":"16","author":"Harris","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"irv230005r38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2019.1635968","article-title":"Recommendations for integrating peer mentors in hospital-based addiction care.","volume":"41","author":"Englander","year":"2020","journal-title":"Subst Abus"},{"key":"irv230005r39","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108434","article-title":"Forty-eight years of research on psychosocial interventions in the treatment of opioid use disorder: aA scoping review.","volume":"218","author":"Wild","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"irv230005r40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/add.15674","article-title":"Effects of brief substance use interventions delivered in general medical settings: a systematic review and meta-analysis.","volume":"117","author":"Tanner-Smith","year":"2022","journal-title":"Addiction"},{"key":"irv230005r41","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3389\/fpsyg.2019.01052","article-title":"Lived experience in new models of care for substance use disorder: a systematic review of peer recovery support services and recovery coaching.","volume":"10","author":"Eddie","year":"2019","journal-title":"Front Psychol"},{"issue":"11","key":"irv230005r42","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s11606-022-07618-x","article-title":"A taxonomy of hospital-based addiction care models: a scoping review and key informant interviews.","volume":"37","author":"Englander","year":"2022","journal-title":"J Gen Intern Med"},{"key":"irv230005r43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108253","article-title":"Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma.","volume":"215","author":"Bhatraju","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"irv230005r44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242165","article-title":"Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018.","volume":"15","author":"Capizzi","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"irv230005r45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/ADM.0000000000000928","article-title":"Trends in hospitalizations for serious infections among people with opioid use disorder in Ontario, Canada.","volume":"16","author":"Gomes","year":"2022","journal-title":"J Addict Med"},{"issue":"23","key":"irv230005r46","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1001\/jama.2023.21288","article-title":"Trends in before medically advised discharges for patients with opioid use disorder, 2016-2020.","volume":"330","author":"Thakrar","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"irv230005r47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/jhm.12893","article-title":"Management of opioid use disorder and associated conditions among hospitalized adults: a consensus statement from the Society of Hospital Medicine.","volume":"17","author":"Calcaterra","year":"2022","journal-title":"J Hosp Med"},{"issue":"1","key":"irv230005r48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.mcna.2021.09.002","article-title":"Harm reduction in health care settings.","volume":"106","author":"Chan","year":"2022","journal-title":"Med Clin North Am"},{"issue":"5","key":"irv230005r49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11606-017-4289-2","article-title":"Do words matter? stigmatizing language and the transmission of bias in the medical record.","volume":"33","author":"P Goddu","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"S2","key":"irv230005r50","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.2105\/AJPH.2021.306645","article-title":"The harms of constructing addiction as a chronic, relapsing brain disease.","volume":"112","author":"Lie","year":"2022","journal-title":"Am J Public Health"},{"issue":"10","key":"irv230005r52","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine adulteration of the heroin-fentanyl drug supply: a narrative review.","volume":"176","author":"D\u2019Orazio","year":"2023","journal-title":"Ann Intern Med"},{"issue":"12","key":"irv230005r53","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jamainternmed.2021.6215","article-title":"Reconsidering reliance on confirmatory drug testing in a patient with repeated positive urine drug screen results: a teachable moment.","volume":"181","author":"Weiss","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"9","key":"irv230005r54","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/add.15818","article-title":"Clinical management of opioid withdrawal.","volume":"117","author":"Torres-Lockhart","year":"2022","journal-title":"Addiction"},{"issue":"9","key":"irv230005r55","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline.","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"5","key":"irv230005r56","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people.","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"irv230005r57","doi-asserted-by":"crossref","first-page":"e236108","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department\u2013initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"key":"irv230005r58","article-title":"Safety of rapid inpatient methadone initiation protocol: a retrospective cohort study.","volume":"148","author":"Racha","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"irv230005r59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13722-023-00368-z","article-title":"Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.","volume":"18","author":"Thakrar","year":"2023","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"irv230005r60","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000864","article-title":"Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis.","volume":"16","author":"Button","year":"2022","journal-title":"J Addict Med"},{"issue":"4","key":"irv230005r61","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/ADM.0000000000001133","article-title":"Rapid low-dose buprenorphine initiation for hospitalized patients with opioid use disorder.","volume":"17","author":"Sokolski","year":"2023","journal-title":"J Addict Med"},{"key":"irv230005r62","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"irv230005r64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-144-2-200601170-00010","article-title":"Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.","volume":"144","author":"Alford","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"irv230005r65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12954-021-00581-6","article-title":"Acute pain and self-directed discharge among hospitalized patients with opioid-related diagnoses: a cohort study.","volume":"18","author":"Compton","year":"2021","journal-title":"Harm Reduct J"},{"key":"irv230005r66","article-title":"Transitioning off methadone: a qualitative study exploring why patients discontinue methadone treatment for opioid use disorder.","volume":"150","author":"Thakrar","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"12","key":"irv230005r67","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1007\/s11606-020-06115-3","article-title":"Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations.","volume":"35","author":"Buresh","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"10","key":"irv230005r68","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/rapm-2021-103007","article-title":"Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel.","volume":"46","author":"Kohan","year":"2021","journal-title":"Reg Anesth Pain Med"},{"issue":"2","key":"irv230005r69","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"irv230005r70","doi-asserted-by":"crossref","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl.","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"irv230005r71","article-title":"Safety and efficacy of rapid methadone titration for opioid use disorder in an inpatient setting: a retrospective cohort study.","author":"Klaire","journal-title":"J Addict Med"},{"issue":"1","key":"irv230005r72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08897077.2021.2010251","article-title":"\u201cI wanted something that was more flexible\u201d: a qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program.","volume":"43","author":"Checkley","year":"2022","journal-title":"Subst Abus"},{"issue":"S2","key":"irv230005r73","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists.","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"issue":"3","key":"irv230005r74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s11606-022-07939-x","article-title":"Envisioning minimally disruptive opioid use disorder care.","volume":"38","author":"Englander","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"11","key":"irv230005r75","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/jhm.13138","article-title":"Things we do for no reason: avoiding methadone for opioid withdrawal.","volume":"18","author":"Martin","year":"2023","journal-title":"J Hosp Med"},{"issue":"4","key":"irv230005r76","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach.","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"key":"irv230005r77","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109541","article-title":"Development of an intravenous low-dose buprenorphine initiation protocol.","volume":"237","author":"Jablonski","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"38","key":"irv230005r78","doi-asserted-by":"crossref","first-page":"E1049","DOI":"10.1503\/cmaj.190344","article-title":"Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.","volume":"191","author":"Fairbairn","year":"2019","journal-title":"CMAJ"},{"issue":"2","key":"irv230005r79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/jme.2023.73","article-title":"State-specific barriers to methadone for opioid use disorder treatment.","volume":"51","author":"Russoniello","year":"2023","journal-title":"J Law Med Ethics"},{"issue":"11","key":"irv230005r80","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1007\/s11606-021-07360-w","article-title":"Acute care utilization after recovery coaching linkage during substance-related inpatient admission: results of two randomized controlled trials.","volume":"37","author":"Cupp","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"1","key":"irv230005r81","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/08897077.2022.2095078","article-title":"Peer providers and linkage with buprenorphine care after hospitalization: a retrospective cohort study.","volume":"43","author":"Jack","year":"2022","journal-title":"Subst Abus"},{"issue":"1","key":"irv230005r82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000810","article-title":"Peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings\u2014a nNarrative review.","volume":"16","author":"Stack","year":"2022","journal-title":"J Addict Med"},{"key":"irv230005r83","first-page":"12","article-title":"\u201cIf it wasn\u2019t for him, I wouldn\u2019t have talked to them\u201d: qualitative study of addiction peer mentorship in the hospital.","volume":"12","author":"Collins","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"2","key":"irv230005r84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/ANS.0000000000000070","article-title":"Toward cultural safety: nurse and patient perceptions of illicit substance use in a hospitalized setting.","volume":"38","author":"Pauly","year":"2015","journal-title":"ANS Adv Nurs Sci"},{"issue":"3","key":"irv230005r85","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.drugpo.2013.12.010","article-title":"Remaking hospital space: the health care practices of injection drug users in New York City.","volume":"25","author":"Szott","year":"2014","journal-title":"Int J Drug Policy"},{"issue":"5","key":"irv230005r86","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","article-title":"Suboptimal addiction interventions for patients hospitalized with injection drug use\u2013associated infective endocarditis.","volume":"129","author":"Rosenthal","year":"2016","journal-title":"Am J Med"},{"issue":"9","key":"irv230005r87","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jhm.13162","article-title":"Response to substance use during hospitalization: a survey study of current and ideal policies and practices.","volume":"18","author":"Huxley-Reicher","year":"2023","journal-title":"J Hosp Med"},{"issue":"6","key":"irv230005r88","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/dar.13246","article-title":"Non-medical prescription opioid use and in-hospital illicit drug use among people who use drugs.","volume":"40","author":"Parmar","year":"2021","journal-title":"Drug Alcohol Rev"},{"key":"irv230005r89","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103275","article-title":"\u201cYou don\u2019t have to squirrel away in a staircase\u201d: patient motivations for attending a novel supervised drug consumption service in acute care.","volume":"96","author":"Kosteniuk","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"1","key":"irv230005r90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/09687637.2017.1337081","article-title":"Turning a blind eye: implementation of harm reduction in a transitional programme setting.","volume":"25","author":"Pauly","year":"2018","journal-title":"Drugs Educ Prev Policy"},{"issue":"1","key":"irv230005r92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/003335490411900109","article-title":"An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models.","volume":"119","author":"Heller","year":"2004","journal-title":"Public Health Rep"},{"key":"irv230005r93","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.025","article-title":"Patient perspectives on a harm reduction-oriented addiction medicine consultation team implemented in a large acute care hospital.","volume":"204","author":"Hyshka","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"irv230005r94","article-title":"Guideline development in harm reduction: considerations around the meaningful involvement of people who access services.","volume":"4","author":"Adams","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"irv230005r95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","article-title":"Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review.","volume":"14","author":"Marchand","year":"2019","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"24","key":"irv230005r96","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/ajhp\/zxac252","article-title":"Implementation of a multidisciplinary inpatient opioid overdose education and naloxone distribution program at a large academic medical center.","volume":"79","author":"Nguyen","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"irv230005r97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/ADM.0000000000001046","article-title":"In-hospital substance use policies: an opportunity to advance equity, reduce stigma, and offer evidence-based addiction care.","volume":"17","author":"Martin","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"irv230005r98","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/dar.12930","article-title":"Uptake into a bedside needle and syringe program for acute care inpatients who inject drugs.","volume":"38","author":"Brooks","year":"2019","journal-title":"Drug Alcohol Rev"},{"key":"irv230005r99","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.103038","article-title":"\u201cOpening the door to somebody who has a chance.\u201d\u2014the experiences and perceptions of public safety personnel towards a public restroom overdose prevention alarm system.","volume":"88","author":"Buchheit","year":"2021","journal-title":"Int J Drug Policy"},{"key":"irv230005r100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109608","article-title":"Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospital.","volume":"239","author":"Nolan","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"irv230005r101","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103324","article-title":"Hospital policy as a harm reduction intervention for people who use drugs.","volume":"97","author":"Lennox","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"1","key":"irv230005r102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamainternmed.2019.5731","article-title":"Facilitating methadone use in hospitals and skilled nursing facilities.","volume":"180","author":"Pytell","year":"2020","journal-title":"JAMA Intern Med"},{"key":"irv230005r103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108895","article-title":"OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.","volume":"143","author":"Tassey","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"irv230005r104","article-title":"In-hospital methadone enrollment: a novel program to facilitate linkage from the hospital to the opioid treatment program for vulnerable patients with opioid use disorder.","author":"Calcaterra","year":"2023","journal-title":"J Gen Intern Med"},{"key":"irv230005r105","article-title":"Dispensing methadone at hospital discharge: one hospital\u2019s approach to implementing the \u201c72-hour rule\u201d change.","author":"Skogrand","year":"2023","journal-title":"J Addict Med"},{"issue":"3","key":"irv230005r106","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States.","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"13","key":"irv230005r107","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMp1900069","article-title":"Opioid use disorder and Iincarceration\u2014hope for ensuring the continuity of treatment.","volume":"380","author":"Binswanger","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"irv230005r109","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2020.8969","article-title":"Therapies offered at residential addiction treatment programs in the United States.","volume":"324","author":"Beetham","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"irv230005r110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7326\/M22-3049","article-title":"Ending medical complicity with skilled-nursing facility discrimination against people with opioid use disorder.","volume":"176","author":"Cohen","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"irv230005r112","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/ADM.0000000000000833","article-title":"Statewide availability of buprenorphine\/naloxone in acute care hospitals.","volume":"16","author":"Pham","year":"2022","journal-title":"J Addict Med"},{"key":"irv230005r113","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jsat.2019.12.003","article-title":"\u201cNow hospital leaders are paying attention\u201d: a qualitative study of internal and external factors influencing addiction consult services.","volume":"110","author":"Priest","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"irv230005r32","volume-title":"The ASAM Principles of Addiction Medicine","author":"Miller","year":"2019","edition":"6th ed"},{"key":"irv230005r51","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"irv230005r1","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. Accessed October 20, 2023. https:\/\/ghdx.healthdata.org\/gbd-results-tool"},{"key":"irv230005r3","unstructured":"Public Health Agency of Canada. Opioid- and stimulant-related Harms in Canada. Accessed October 5, 2023. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"irv230005r4","doi-asserted-by":"crossref","unstructured":"Spencer? MR, Mini\u00f1o? AM, Warner? M. Drug overdose deaths in the United States, 2001-2021. Accessed October 5, 2023.","DOI":"10.15620\/cdc:122556"},{"key":"irv230005r29","unstructured":"American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Accessed September 24, 2020. https:\/\/www.asam.org\/docs\/default-source\/quality-science\/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2"},{"key":"irv230005r30","unstructured":"US Department of Veterans Affairs, US Department of Defense. VA\/DOD clinical practice guideline for the management of substance use disorders, version 4.0. Accessed July 21, 2023. https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPG.pdf"},{"key":"irv230005r31","unstructured":"British Columbia Centre on Substance Use and B.C. Ministry of Health. A guideline for the clinical management of opioid use disorder. Accessed August 10, 2023. https:\/\/www.bccsu.ca\/care-guidance-publications\/"},{"key":"irv230005r33","unstructured":"National Library of Medicine, National Institutes of Health, US Department of Health and Human Services. PubMed. Accessed August 10, 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/"},{"key":"irv230005r34","unstructured":"John Wiley & Sons, Inc. Cochrane library. Accessed August 10, 2023. https:\/\/www.cochranelibrary.com"},{"key":"irv230005r35","unstructured":"National Library of Medicine, National Institutes of Health. ClinicalTrials.gov. Accessed August 10, 2023. https:\/\/clinicaltrials.gov\/"},{"key":"irv230005r36","unstructured":"Dong? K, Meador? K, Hyshka? E, . Supporting people who use substances in acute care settings during the COVID-19 pandemic: CRISM\u2014interim guidance document. Accessed. https:\/\/crism.ca\/wp-content\/uploads\/2021\/02\/Supporting-people-who-use-substances-in-acute-care-settings-during-the-COVID-19-pandemic-V2-18-Feb-2021.pdf"},{"key":"irv230005r37","unstructured":"Canadian Research Initiative in Substance Misuse. Guidance document on the management of substance use in acute care. Accessed August 10, 2023. https:\/\/crismprairies.ca\/management-of-substance-use-in-acute-care-settings-in-alberta-guidance-document\/"},{"key":"irv230005r63","unstructured":"Center for Drug Evaluation and Research. FDA Drug safety communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Accessed August 9, 2023. from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications"},{"key":"irv230005r91","unstructured":"Harm Reduction International. What is harm reduction? Accessed July 11, 2023. https:\/\/hri.global\/what-is-harm-reduction\/"},{"key":"irv230005r108","unstructured":"American Society of Addiction Medicine. About the ASAM criteria. Accessed August 9, 2023. https:\/\/www.asam.org\/asam-criteria\/about-the-asam-criteria"},{"key":"irv230005r111","unstructured":"Network for the Improvement of Addiction Treatment. Workbook: an introduction to the NIATx model of process improvement. Accessed August 11, 2023. https:\/\/niatx.wisc.edu\/wp-content\/uploads\/sites\/1871\/2023\/02\/NIATxWorkbook_2.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2818022\/jamainternal_englander_2024_rv_230005_1717424145.08177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:19:47Z","timestamp":1717413587000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2818022"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2023.7282","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}